Please assess the completion status of the following clinical trial:

Trial Title: The Rosuvastatin In TrAnsplant Recipients Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Renal transplant recipients with stable renal function (plasma creatinine \< 200 µmol/L)~* Renal transplant recipients on an everolimus and fluvastatin based therapy for minimum 3 months prior to inclusion~* \> 18 years of age~* Male patient or female patient without childbearing potential (surgically sterilized or postmenopausal) or if female of childbearing potential; is not lactating, has a negative pregnancy test at screening and is willing to utilize an effective method of contraception throughout the study period and for 90 days following discontinuation of the study drugs~* Signed informed consent~Exclusion Criteria:~* Patients experiencing an acute rejection episode within 2 weeks before or after inclusion, whether proven by biopsy or not~* Patients with a known hypersensitivity to rosuvastatin~* Change in enzyme inducing or inhibiting drugs within the last 2 weeks prior to and throughout the study \[e.g. barbiturates, rifampicin, ketoconazole, erythromycin, cimetidine and similar drugs\]~* Pregnant or nursing mothers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: EXPERIMENTAL): Rosuvastatin treatment for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).